We recently published a list of 10 Stocks Investors Dumped Fast. In this article, we are going to take a look at where ...

We recently published a list of Was Jim Cramer Right About These 11 Stocks? In this article, we are going to take a look at where Sarepta Therapeutics Inc. (NASDAQ:SRPT) stands against other stocks ...

Fintel reports that on June 6, 2025, Scotiabank upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from Sector ...

The Platform Technology Designation, which predates the current FDA leadership, is designed to streamline the drug ...

Sarepta Therapeutics (NasdaqGS:SRPT) saw its share price rise by 19% over the past month, a move that notably outpaced the broader market's 1% increase for the week and the 13% gain over the year.

The company is one of the first to receive a “platform technology designation,” which could speed the review of certain gene ...

Sarepta Therapeutics Inc.’s stock tumbled 23% on Tuesday after the biotech said a patient who used its gene therapy Elevidys for the rare disease Duchenne muscular dystrophy has died of acute ...

Sarepta Therapeutics stock is diving after the company released its Q1 results. The company reports quarterly losses of $3.42 per share which missed the analyst consensus estimate of losses of 95 ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...

The latest analyst rating for Sarepta Therapeutics (NASDAQ:SRPT) was provided by Scotiabank, and Sarepta Therapeutics upgraded their sector outperform rating. The last upgrade for Sarepta ...